10th IAS Conference on HIV Science (IAS 2019) in Mexico City
Simon Collins, HIV i-Base
The 10th IAS Conference on HIV Science (IAS 2019) in Mexico City was held from 21 – 24 July 2019.
The programme is posted online, with abstracts and PowerPoint slides available for many of the presentations.
Reports in the last issues of HTB focussed on:
- New antiretroviral drugs.
- ART strategies with new and existing drugs.
- An important (and optimistic) update on neural tube defects with dolutegravir, with a comprehensive review of the latest data.
- Updates to WHO treatment guidelines
HTB reports in this issue include:
- Four days on, three days off is NOT as effective as daily ART: French study results need to be interpreted with caution
- Switching to bictegravir/F/TAF in virally suppressed participants – including analyses by baseline drug resistance
- Dolutegravir-based first-line non-inferior to efavirenz-based ART but associated with substantial weight gain: results from the ADVANCE study
- PK advantages of TAF/FTC over TDF/FTC for HIV PrEP might compensate for low adherence: sub-analysis of DISCOVER study